Shattuck Labs, Inc. Common Stock STTK
i
Market datapartial · fetched 2026-11-13T02:09:25.734Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T22:08:40.420919197Z
FundamentalsAlpha Vantage · unavailable
Shattuck Labs, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.30 | 753.8% | 56.0% | |||
| 25Δ | 3.82 | 674.0% | 44.8% | |||
| 30Δ | 4.21 | 604.4% | 36.9% | |||
| 35Δ | 4.55 | 540.4% | 31.0% | |||
| 40Δ | 4.88 | 476.4% | 25.0% | |||
| 45Δ | 10.55 | 800.0% | 157.1% | 5.16 | 433.7% | 20.8% |
| 50Δ | 9.10 | 800.0% | 125.6% | 5.40 | 403.4% | 17.6% |
| 55Δ | 6.90 | 707.6% | 77.8% | 5.65 | 373.0% | 14.4% |
| 60Δ | 5.45 | 600.2% | 47.2% | 5.90 | 342.7% | 11.1% |
| 65Δ | 4.72 | 567.6% | 34.1% | |||
| 70Δ | 4.21 | 567.5% | 26.8% | |||
| 75Δ | 3.71 | 572.7% | 20.8% | |||
| 80Δ | 3.22 | 581.6% | 15.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.30
- IV
- 753.8%
- B/E move
- 56.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.82
- IV
- 674.0%
- B/E move
- 44.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.21
- IV
- 604.4%
- B/E move
- 36.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.55
- IV
- 540.4%
- B/E move
- 31.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.88
- IV
- 476.4%
- B/E move
- 25.0%
45Δ
- Pseudo strike
- 10.55
- IV
- 800.0%
- B/E move
- 157.1%
- Pseudo strike
- 5.16
- IV
- 433.7%
- B/E move
- 20.8%
50Δ
- Pseudo strike
- 9.10
- IV
- 800.0%
- B/E move
- 125.6%
- Pseudo strike
- 5.40
- IV
- 403.4%
- B/E move
- 17.6%
55Δ
- Pseudo strike
- 6.90
- IV
- 707.6%
- B/E move
- 77.8%
- Pseudo strike
- 5.65
- IV
- 373.0%
- B/E move
- 14.4%
60Δ
- Pseudo strike
- 5.45
- IV
- 600.2%
- B/E move
- 47.2%
- Pseudo strike
- 5.90
- IV
- 342.7%
- B/E move
- 11.1%
65Δ
- Pseudo strike
- 4.72
- IV
- 567.6%
- B/E move
- 34.1%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 4.21
- IV
- 567.5%
- B/E move
- 26.8%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 3.71
- IV
- 572.7%
- B/E move
- 20.8%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 3.22
- IV
- 581.6%
- B/E move
- 15.5%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
SVRA
Savara Inc. is a lung disease orphan company. The company is headquartered in Austin, Texas.
More →SYRE
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody…
More →TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare…
More →TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions.…
More →TECH
Description unavailable
More →TECX
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients…
More →